ArticleCancer cell2024
Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies.
Article in Cancer cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 62 citations in OpenAlex.
- Genomic instability, postoperative recurrence and therapeutic vulnerabilities in resectable non‑small cell lung cancer (Review).Oncology reports · 2026Review
- Review
- Charting intratumor heterogeneity from bench to bedside.Nature cancer · 2026Review
- Specificity-driven cell-gene graph learning identifies rare cell states in single-cell and spatial transcriptomic data.Advanced biotechnology · 2026Article
- Immunological Significance of the ICI-PIT-ICI Sequence in Recurrent Oral Cancer: A Narrative Review with Illustrative Cases.Diagnostics (Basel, Switzerland) · 2026Review
- Targeting CD3L1-NRP2 disarms myeloid-driven tumor immune evasion.EMBO molecular medicine · 2026Article
- The sleeping threat: targeting cancer dormancy to transform metastasis therapy.Nature reviews. Cancer · 2026Review
- "Immune senescence and dormant tumor cells: reconceptualizing breast cancer recurrence as an affliction of aging and chronic inflammation".Annals of medicine and surgery (2012) · 2026Review
- Breathing new life into T-cell receptor-engineered T-cell therapy in solid tumors: enhancing strategies to expand the universality of precision therapy.Experimental hematology & oncology · 2026Review
- Striking the right balance with type I interferon signalling in cancer.Nature reviews. Cancer · 2026Review
- Intrinsic and extrinsic regulators of cancer dormancy and awakening.Journal of the National Cancer Center · 2026Review
- Ubiquitination of DDX21 by HERC2 induces a dormancy-like phenotype via the NUCKS1-p21/p27 axis to promote radio-resistance in colorectal cancer cells.Cell death & disease · 2026Article
- Article
- Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance.Molecular oncology · 2026Review
- The Osteoblastic Microenvironment Determines the Fate of Breast Cancer Cells Disseminated in the Bone Marrow.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Therapeutic efficacy of cancer stem cell-based vaccine in colorectal murine model: reduced tumor growth and prolonged survival.BMC cancer · 2026Article
- IL-18-Mediated Tumor Immune Evasion.Current issues in molecular biology · 2026Review
- Dual role of IFNγ in reprogramming the undifferentiated pleomorphic sarcoma cell line JBT19 towards cytotoxic chemotherapy and antitumor immunity.Oncology letters · 2026Article
- Biopsy RNA-seq captures TROP-2-linked migration and clonal resistance to forecast aggressiveness in metastatic melanoma.Journal of experimental & clinical cancer research : CR · 2026Article
- Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 3 institutions in 2 countries.
Funding
Abstract
The period between "successful" treatment of localized breast cancer and the onset of distant metastasis can last many years, representing an unexploited window to eradicate disseminated disease and prevent metastases. We find that the source of recurrence-disseminated tumor cells (DTCs) -evade endogenous immunity directed against tumor neoantigens. Although DTCs downregulate major histocompatibility complex I, this does not preclude recognition by conventional T cells. Instead, the scarcity of interactions between two relatively rare populations-DTCs and endogenous antigen-specific T cells-underlies DTC persistence. This scarcity is overcome by any one of three immunotherapies that increase the number of tumor-specific T cells: T cell-based vaccination, or adoptive transfer of T cell receptor or chimeric antigen receptor T cells. Each approach achieves robust DTC elimination, motivating discovery of MHC-restricted and -unrestricted DTC antigens that can be targeted with T cell-based immunotherapies to eliminate the reservoir of metastasis-initiating cells in patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.